Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.

Fish oil beneficial against psoriasis

09 Mar 2020

The use of fish oil and its components may yield favourable effects on psoriasis and its comorbidities, namely obesity, cardiovascular disease and metabolic disease, when combined with conventional treatments, as reported in a recent study.

Researchers performed a quantitative systematic review and searched multiple online databases for studies evaluating the efficacy and safety of fish oil and omega-3 polyunsaturated fatty acids (ω-3 PUFAs) in the treatment of psoriasis. They also conducted a meta-analysis to assess the effects of the said intervention for managing comorbidities.

The search yielded 75 studies, of which 18 randomized controlled trials involving 927 participants met inclusion criteria. Pooled data showed that the use of fish oil or ω-3 PUFAs alone had a null effect on the Psoriasis Area and Severity Index (PASI) score (p=0.47), lesion area (p=0.34) or pruritus (p=0.62).

However, when used in addition to conventional treatments, fish oil or ω-3 PUFAs conferred reductions in PASI score (mean difference [MD], −3.92, 95 percent confidence interval [CI], −6.15 to −1.69; p=0.0006) and lesion area (MD, −30.00, 95 percent CI, −33.82 to −26.18; p<0.0001).

Subgroup analysis showed no significant differences in adverse events between groups that received fish oil (risk ratio [RR], 4.45, 95 percent CI, 0.52–38.16; p=0.17) or ω-3 PUFAs (RR, 1.41, 95 percent CI, 0.53–3.74; p=0.49) and the control.

Finally, fish oil or ω-3 PUFAs produced improvements in certain risk factors for obesity, cardiovascular disease and metabolic disease in psoriatic patients, as well as regulated several inflammatory mediators.

Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.